Making the compound Amanitin available for cancer therapies

Our mission is to research and develop drugs for cancer patients to provide them
with a targeted, tailor-made and highly effective treatment option

ADC Drug Development

We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.

ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.


PR: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
24 March 2023
PR: Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
16 December 2022
PR: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022
14 December 2022
PR: Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022
10 November 2022

Meet us

BIO Europe Spring
20 March 2023
Deutsche Biotechnologietage
28 March 2023
AACR Annual Meeting
14 April 2023
PEGS Boston 2023
25 May 2023

Partner Informationen

Magenta Therapeutics to Explore Strategic Alternatives
2 February 2023
Read more
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
25 January 2023
Read more
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
3 January 2023
Read more

© Heidelberg Pharma AG. All rights reserved.